Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica

Volumn 93, Issue 11, 2008, Pages 1723-1727

  Girodon, François ^a,b,e   Schaeffer, Céline ^a   Cleyrat, Cédric ^c   Mounier, Morgane ^b   Lafont, Ingrid ^a   Dos Santos, Frédéric ^a   Vidal, Aurélie ^a   Maynadié, Marc ^a   Hermouet, Sylvie ^c,d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Team 12   (France)

^d Centre Hopitalier Universitaire   (France)

^e HÔPITAL DU BOCAGE   (France)

Author keywords

Allele specific real time quantitative PCR; Essential thrombocythemia; Hydroxyurea; JAK2V617F; Myeloproliferative neoplasm; Polycythemia vera

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

ADULT; AGED; ALLELISM; ARTICLE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE MUTATION; GRANULOCYTE; HUMAN; HUMAN CELL; MALE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PROGNOSIS; THROMBOCYTHEMIA; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTISICKLING AGENTS; COHORT STUDIES; DNA PRIMERS; FEMALE; GRANULOCYTES; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 55549132620     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13081     Document Type: Article

References (17)

1. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Girodon F, Lippert E, Mossuz P, Dobo I, Boiret-Dupre N, Lesesve JF, et al. JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit. Haematologica 2007;92:431-2.
4. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-9.
5. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-9.
6. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41-8.
7. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 2007;21:2210-2.
8. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109:2279-84.
9. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007;109:4105.
10. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
11. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 2006;108:2037-40.
12. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-6.
13. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-7.
14. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
15. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007;109:1241-3.
16. Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, Perrault-Hu F, et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 2007;21:1128-30.
17. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-9.